Breaking News

Curia Expands Cell Line Development Offering with CHOZN Platform

Signs license agreement with MilliporeSigma to support production of proteins and antibodies.

Curia, a contract research, development, and manufacturing organization (CDMO), signed a licensing agreement with MilliporeSigma that enables Curia and its clients to use the CHOZN GS-/- cell line for production of therapeutic proteins and antibodies. Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers. CHOZN platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters